Advertisement
Advertisement

ACRS

ACRS logo

Aclaris Therapeutics, Inc.

3.58
USD
Sponsored
+0.19
+5.46%
Feb 06, 15:59 UTC -5
Closed
exchange

After-Market

3.57

-0.01
-0.14%

ACRS Earnings Reports

Positive Surprise Ratio

ACRS beat 28 of 40 last estimates.

70%

Next Report

Date of Next Report
Mar 03, 2026
Estimate for Q4 25 (Revenue/ EPS)
$1.98M
/
-$0.15
Implied change from Q3 25 (Revenue/ EPS)
-40.07%
/
+25.00%
Implied change from Q4 24 (Revenue/ EPS)
-78.53%
/
-85.15%

Aclaris Therapeutics, Inc. earnings per share and revenue

On Nov 06, 2025, ACRS reported earnings of -0.12 USD per share (EPS) for Q3 25, beating the estimate of -0.13 USD, resulting in a 12.85% surprise. Revenue reached 3.30 million, compared to an expected 1.43 million, with a 130.15% difference. The market reacted with a +0.44% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 9 analysts forecast an EPS of -0.15 USD, with revenue projected to reach 1.98 million USD, implying an increase of 25.00% EPS, and decrease of -40.07% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, Aclaris Therapeutics, Inc. reported EPS of -$0.12, beating estimates by 12.85%, and revenue of $3.30M, 130.15% above expectations.
The stock price moved up 0.44%, changed from $2.26 before the earnings release to $2.27 the day after.
The next earning report is scheduled for Mar 03, 2026.
Based on 9 analysts, Aclaris Therapeutics, Inc. is expected to report EPS of -$0.15 and revenue of $1.98M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement